Introducing REZZAYO^® (rezafungin), the first once weekly echinocandin indicated for the treatment of invasive candidiasis in adults. Consideration should be given to official guidance on the appropriate use of antifungal agents.¹ With a renowned faculty of Professor Oliver Cornely, Professor Tihana Bicanic and Professor Matteo Bassetti.

References

1. REZZAYO^® (rezafungin). Summary of Product Characteristics. Napp 2024.

Agenda

19:00-20:00 BST

• Key challenges in the management of invasive candidiasis​
• The data from the REZZAYO^® clinical trial programme​
• The potential benefits of REZZAYO^® in the ICU, ward and for the outpatient
• Q&A
   

Speaker Professor Darius Armstrong-James Professor of Infectious Diseases and Medical Mycology, Imperial College London

19:30 - Welcome and Session Objectives
19:45 - Meeting the challenges of treating invasive candidiasis in the UK
- Understanding the current challenges we face in the UK
- The healthcare burden of treating IC across different care settings
- The data from the REZZAYO® rezafungin clinical trial programme
- Meeting the challenges - can REZZAYO® rezafungin provide a solution in the UK?
20:15 - Principles into practice - facilitated discussion
21:00 - Action plans and meeting close (21:30)

Coach transfer from ECCMID 2024 conference to the venue available